The proposal by Lindqvist and colleagues 1 of four essential medicines for the control of terminal symptoms is commendable. Having a finite essential medication list facilitates prescribers to prescribe and pharmacies to stock and supply medications to support end-of-life care in the community. The differences between the two lists are the choices of benzodiazepine and anticholinergic, and the inclusion of metoclopramide. Both midazolam and clonazepam are used for symptom control at the end of life. However midazolam's short duration of action means a syringe driver is required for lasting effect, which may be unavailable at short notice. Therefore, with community patients in mind, we proposed clonazepam as our benzodiazepine of choice. In Australia, clonazepam is also eligible for government subsidy, thus cheaper than injectable midazolam for patients. We selected hyoscine butylbromide because of its inability to cross the blood brain barrier to minimize central anticholinergic effects, particularly sedation and delirium, for patients who are still conscious.
Each list was developed to facilitate high-quality symptom control at the end of life for community patients. Regional licensing and subsidy will influence the exact medications on such lists. However with essential medication lists, the imperative is to educate both prescriber and pharmacist to ensure the medications prescribed at the end of life will be available for the patient in his or her time of great need. Without education, the risk is the prescriber, through personal preference, will prescribe medications outside the list and compromise the symptom control of the patient at the end of life simply because the pharmacist is unable to anticipate which medicines to stock.
